Immix Biopharma, Inc. (IMMX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IMMX SEC filings page.
This page shows Immix Biopharma, Inc. (IMMX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Immix funds a research-heavy operation through external financing, with cash consumption rising faster than internally generated resources.
In FY2025, financing inflow of$107.4M was more than four times operating cash use of$23.9M , so balance-sheet expansion came chiefly from financing sources rather than internally generated cash.
R&D investment climbed from
Debt-to-equity dropped from 0.7x in FY2024 to 0.1x in FY2025, indicating that new funding did not primarily leave the company more debt-financed. Total assets reached
Financial Health Signals
We are recalculating Immix Biopharma, Inc.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Immix Biopharma, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Immix Biopharma, Inc. reported a net loss of $29.4M while operations used $23.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Immix Biopharma, Inc.'s EBITDA was -$12.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 85.7% from the same quarter a year earlier. Against the prior quarter it is down 15.5%.
Immix Biopharma, Inc. reported -$11.6M in net income in Q2 2026. This represents a decrease of 74.5% from the same quarter a year earlier. Against the prior quarter it is down 14.6%.
Immix Biopharma, Inc. earned -$0.18 per diluted share (EPS) in Q2 2026. It is unchanged from the prior quarter.
Not reported for Q2 2026.
Cash & Balance Sheet
Immix Biopharma, Inc. recorded an outflow of $11.8M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 116.2% from the same quarter a year earlier. Against the prior quarter it is down 19.2%.
Immix Biopharma, Inc. held $225.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Immix Biopharma, Inc.'s ROE was -5.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 137.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.9 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Immix Biopharma, Inc. invested $5.3M in research and development in Q2 2026. This represents an increase of 34.3% from the same quarter a year earlier. Against the prior quarter it is down 10.8%.
Immix Biopharma, Inc. invested $21K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 83.5% from the same quarter a year earlier. Against the prior quarter it is down 35.2%.
Not reported for Q2 2026.
IMMX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $5.3M+34.3% | $6.0M+202.8% | N/A | $4.6M+3.1% | $4.0M+78.6% | $2.0M-39.2% | N/A | $4.4M+111.1% |
| SG&A Expenses | $7.1M+159.5% | $4.8M+78.1% | N/A | $3.1M+4.4% | $2.7M+10.8% | $2.7M+15.6% | N/A | $2.9M+22.0% |
| Operating Income | -$12.5M-85.4% | -$10.8M-130.7% | N/A | -$7.7M-3.6% | -$6.7M-42.9% | -$4.7M+16.2% | N/A | -$7.4M-63.5% |
| EBITDA | -$12.3M-85.7% | -$10.7M-130.8% | N/A | -$7.5M-2.2% | -$6.6M-41.9% | -$4.6M+16.9% | N/A | -$7.4M-62.9% |
| Income Tax | $14K+60.7% | N/A | N/A | $8K-30.7% | $9K-13.2% | $10K+11.1% | N/A | $11K+63.7% |
| Net Income | -$11.6M-74.5% | -$10.1M-122.1% | N/A | -$7.6M-6.1% | -$6.6M-50.8% | -$4.5M+13.6% | N/A | -$7.1M-67.0% |
| EPS (Basic) | -$0.18+18.2% | -$0.18-20.0% | -$0.28-75.0% | -$0.240.0% | -$0.22-46.7% | -$0.15+31.8% | -$0.16+33.3% | -$0.24-4.3% |
| EPS (Diluted) | -$0.18 | -$0.18 | -$0.28 | -$0.240.0% | -$0.22-46.7% | -$0.15+31.8% | -$0.16+33.3% | -$0.24 |
| Diluted Shares (Avg) | 64M | 55M | N/A | 32M+8.5% | 30M+4.2% | 30M+26.7% | N/A | 29M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
IMMX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $239.1M+1429.3% | $95.8M+381.7% | $104.8M+356.9% | $20.1M-20.1% | $15.6M-45.8% | $19.9M-42.1% | $22.9M+15.2% | $25.1M+11.9% |
| Current Assets | $233.8M+1796.8% | $92.3M+449.9% | $101.2M+401.2% | $16.6M-27.1% | $12.3M-54.9% | $16.8M-49.0% | $20.2M+2.1% | $22.8M+1.9% |
| Cash & Equivalents | $225.5M+1837.6% | $79.3M+397.8% | $93.9M+431.2% | $15.9M-19.0% | $11.6M-51.5% | $15.9M-45.7% | $17.7M+1.0% | $19.7M+0.6% |
| Short-Term Investments | $6.6M | $11.3M | $6.5M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $2.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $10.2M-7.2% | $11.5M+11.2% | $11.0M+13.9% | $11.8M+55.7% | $11.0M+122.1% | $10.3M+53.3% | $9.7M+160.5% | $7.6M+168.7% |
| Current Liabilities | $9.3M-7.1% | $10.5M+13.2% | $10.1M+16.4% | $10.9M+65.3% | $10.0M+156.5% | $9.3M+64.5% | $8.7M+133.4% | $6.6M+132.3% |
| Non-Current Liabilities | $891K-8.4% | $912K-7.9% | $934K-7.5% | $965K-6.0% | $972K-6.8% | $991K-6.4% | $1.0M | $1.0M |
| Total Equity | $228.9M+4819.7% | $84.4M+779.4% | $93.8M+607.8% | $8.3M-52.9% | $4.7M-80.5% | $9.6M-65.6% | $13.3M-19.2% | $17.6M-11.2% |
| Retained Earnings | -$126.1M-46.3% | -$114.5M-44.0% | -$104.5M-39.2% | -$93.8M-33.6% | -$86.2M-36.7% | -$79.6M-35.6% | -$75.0M-40.5% | -$70.2M-45.3% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
IMMX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.7M-121.0% | -$9.8M-483.2% | -$11.0M-647.2% | -$5.9M-46.3% | -$5.3M-1.0% | -$1.7M+56.0% | -$1.5M+44.9% | -$4.0M-30.8% |
| Depreciation & Amortization | $131K+63.9% | $131K+121.0% | $91K+119.2% | $135K+420.6% | $80K+228.6% | $59K+148.1% | $41K+1243.9% | $26K+1775.9% |
| Stock-Based Compensation | N/A | $576K-33.7% | N/A | N/A | N/A | $868K-7.9% | N/A | N/A |
| Capital Expenditures | $21K-83.5% | $32K-52.0% | $165K-67.4% | $372K+37.2% | $128K+31.5% | $68K-77.6% | $507K+3748.8% | $272K |
| Free Cash Flow | -$11.8M-116.2% | -$9.9M-462.5% | -$11.2M-464.4% | -$6.3M-45.7% | -$5.4M-1.6% | -$1.8M+57.5% | -$2.0M+26.3% | -$4.3M |
| Investing Cash Flow | $2.7M+2191.7% | -$4.8M-6990.0% | -$6.6M-1210.5% | -$372K-37.2% | -$128K-31.5% | -$68K+77.6% | -$507K-3748.8% | -$272K |
| Financing Cash Flow | $155.3M | -$38K | $95.7M | $10.6M | N/A | N/A | $0-100.0% | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
IMMX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -5.1%+137.3pp | -12.0%+35.4pp | N/A | -91.8%-51.0pp | -142.3%-123.9pp | -47.3%-28.5pp | N/A | -40.7%-19.1pp |
| Return on Assets | -4.8%+37.5pp | -10.5%+12.3pp | N/A | -37.8%-9.3pp | -42.4%-27.1pp | -22.8%-7.5pp | N/A | -28.4%-9.4pp |
| Current Ratio | 25.13+23.9x | 8.76+7.0x | 10.01+7.7x | 1.53-1.9x | 1.23-5.8x | 1.80-4.0x | 2.33-3.0x | 3.47-4.4x |
| Debt-to-Equity | 0.04-2.3x | 0.14-0.9x | 0.12-0.6x | 1.43+1.0x | 2.36+2.2x | 1.07+0.8x | 0.73+0.5x | 0.43+0.3x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Immix Biopharma, Inc. IMMX | FY2025 | N/A | -$29.4M | N/A | $799.2M | — |
| BeyondSpring Inc. BYSI | FY2025 | $0 | -$1.0M | N/A | $32.4M | — |
| Adicet Bio, Inc. ACET | FY2025 | N/A | -$116.8M | N/A | $60.8M | — |
| OS Therapies Incorporated OSTX | FY2025 | N/A | -$28.8M | N/A | $75.8M | — |
| NRX Pharmaceuticals, Inc. NRXP | FY2025 | $1.2M | -$28.6M | N/A | $125.8M | 43/100 |
Where Immix Biopharma, Inc. Ranks
Frequently Asked Questions
Is Immix Biopharma, Inc. profitable?
No, Immix Biopharma, Inc. (IMMX) reported a net income of -$29.4M in fiscal year 2025.
What is Immix Biopharma, Inc.'s EBITDA?
Immix Biopharma, Inc. (IMMX) had EBITDA of -$29.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Immix Biopharma, Inc.'s return on equity (ROE)?
Immix Biopharma, Inc. (IMMX) has a return on equity of -31.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Immix Biopharma, Inc.'s free cash flow?
Immix Biopharma, Inc. (IMMX) recorded an outflow of $24.7M in free cash flow during fiscal year 2025. This represents a -56.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Immix Biopharma, Inc.'s operating cash flow?
Immix Biopharma, Inc. (IMMX) recorded an outflow of $23.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Immix Biopharma, Inc.'s total assets?
Immix Biopharma, Inc. (IMMX) had $104.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Immix Biopharma, Inc.'s capital expenditures?
Immix Biopharma, Inc. (IMMX) invested $733K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Immix Biopharma, Inc. spend on research and development?
Immix Biopharma, Inc. (IMMX) invested $16.3M in research and development during fiscal year 2025.
What is Immix Biopharma, Inc.'s current ratio?
Immix Biopharma, Inc. (IMMX) had a current ratio of 10.01 as of fiscal year 2025, which is generally considered healthy.
What is Immix Biopharma, Inc.'s debt-to-equity ratio?
Immix Biopharma, Inc. (IMMX) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Immix Biopharma, Inc.'s return on assets (ROA)?
Immix Biopharma, Inc. (IMMX) had a return on assets of -28.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Immix Biopharma, Inc.'s P/E ratio?
Immix Biopharma, Inc. (IMMX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $799.2M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Immix Biopharma, Inc.'s price-to-sales ratio?
Immix Biopharma, Inc. (IMMX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $799.2M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Immix Biopharma, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Immix Biopharma, Inc. (IMMX) held $100.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.9M over that year. Dividing the one by the other, the reported balance equals about 50 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Immix Biopharma, Inc.'s Piotroski F-Score?
Immix Biopharma, Inc. (IMMX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Immix Biopharma, Inc.'s earnings high quality?
Immix Biopharma, Inc. (IMMX) reported a net loss of $29.4M while operations used $23.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.